--- canonical_url: https://www.stockexpertai.com/earnings/bg last_updated: 2026-05-09T12:50:15.249Z --- # Bunge Global S.A. (BG) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T12:50:14.607Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $124.94 (▲ 0.96%) | fmp:quote | | Market Cap | $24.2B | fmp:profile | | 52w range | $71.60 – $133.93 | fmp:quote | | Earnings | Wed 29 Jul | fmp:earnings-history | | EPS estimate | $1.98 (+51% YoY) | fmp:earnings-estimate | | Revenue estimate | $23.4B | fmp:earnings-estimate | | Beat streak | 5/4 | fmp:earnings-history | | Rating | B- (overall 3/5) | fmp:ratings | | Analyst median target | $130 (+4.0% upside) | fmp:price-target-consensus | | MoonshotScore | 49/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## Bunge Global S.A. — Q4 FY2026 Expectations Q4 consensus: revenue $23.4B^{[FMP est]}, EPS $1.98^{[FMP est]}. 5 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B- · **Stance:** HOLD · **Council:** 2/6 · **Moonshot:** 49 = MoonshotScore 49^{[9-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (6 metrics) ### 1. Fy26 Eps Guidance Bunge is increasing its full year 2026 adjusted EPS guidance from $7.50-$8.00 to $9.00-$9.50. > "Based on what we can see today, including the strength of Q1 and the forward curves as we look at the balance of the year, we are increasing our full year adjusted EPS guidance range to $9 to $9.50, and that's up from the $7.50 to $8 we provided on our fourth quarter call." > — Gregory Heckman, CEO, Expectation / Guide · Q1 FY2026 ### 2. Net Interest Expense Guidance Bunge now expects net interest expense in the range of $620 million to $660 million for 2026, which is up from its previous range of $575 million to $625 million. > "Net interest expense in the range of $620 million to $660 million, which is up from our previous range of $575 million to $625 million, primarily due to higher short-term debt levels supporting an expected increase in working capital." > — John Neppl, CFO, Expectation / Guide · Q1 FY2026 ### 3. Capex Guidance Bunge expects capital expenditures in the range of $1.5 billion to $1.7 billion for 2026. > "Capital expenditures in the range of $1.5 billion to $1.7 billion and depreciation and amortization of approximately $975 million." > — John Neppl, CFO, Expectation / Guide · Q1 FY2026 ### 4. Tropical Oils Specialty Ingredients Grain Merchandising Milling Bunge expects Tropical Oils and Specialty Ingredients and Grain Merchandising and Milling segment results to be lower for full year 2026. > "Tropical Oils and Specialty Ingredients and Grain Merchandising and Milling segment results are expected to be lower and corporate and other results are expected to be in line." > — John Neppl, CFO, Investor Focus · Q1 FY2026 ### 5. Soybean Softseed Processing Refining Bunge expects Soybean and Softseed Processing and Refining segment results to be higher for full year 2026. > "For the full year compared to our previous outlook, Soybean and Softseed Processing and Refining segment results are forecasted to be higher." > — John Neppl, CFO, Investor Focus · Q1 FY2026 ### 6. Viterra Synergies Bunge notes that Viterra cost synergies are running ahead of plan, and they've identified significant network and commercial opportunities. > "Viterra cost synergies are running ahead of plan, and we've identified significant network and commercial opportunities." > — Gregory Heckman, CEO, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 10.0 | strong | Q1 vs Q2: fast growth (+71.2%) | | Gross Margin | 1.0 | weak | Q1: low margin (7.5%, capital-intensive or commodity) | | Operating Leverage | 1.0 | weak | op margin average (5.1%) | | Cash Runway | 3.0 | weak | FCF negative ($-0.9B, external financing needed) | | R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) | | Price Momentum | 7.0 | strong | RSI 49.9 balanced, 50d above | | News Sentiment | 9.0 | strong | strong buy consensus (89%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +4.0% | | Ken Griffin | bull | flow · 50d MA above | | Jim Simons | neutral | quant · RSI 50 | | Klarman | neutral | value · target upside +4.0% | | Buffett | neutral | quality · ROE score 2/5 | | Munger | neutral | valuation · target upside +4.0% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Moderate - **Margin of Safety:** Weak - **Interest Coverage:** Adequate - **ROIC vs WACC:** Tight **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 49.9 — dengeli — yön sinyali zayıf - **50d MA:** $124 — hisse %0.9 üstünde — kısa vadeli destek - **200d MA:** $101 — hisse %23.2 üstünde — uzun vadeli destek - **Volume (10d):** -22% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $1.31 | $1.09 | BEAT | -0.7% | | Q3 FY25 | $2.27 | $1.94 | BEAT | -0.8% | | Q4 FY25 | $1.99 | $1.81 | BEAT | -2.8% | | Q1 FY26 | $1.83 | $0.97 | +88.7% EPS | +0.6% | Q1 (April 29, 2026): EPS $1.83 vs $0.97 est^[FMP], +88.7% beat. D+1 movement: +0.6%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $1.98 + CapEx discipline** Threshold: EPS > $1.98^{[FMP est]}. Target: Break above median target $130^{[FMP target]}; high target $150^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $1.98 + CapEx < $336.0M** Threshold: EPS ≈ $1.98^{[FMP est]}, Q4 CapEx < $336.0M^[FMP]. Target: Consolidation in the band between current $125^[FMP] and median $130^[FMP]. ### Scenario C · Miss **EPS < $1.92 or CapEx ≥ $336.0M** Threshold: EPS < $1.92^{[FMP est×0.97]}. Target: Current $125 below SMA200 $101^[FMP], if rejection continues, $86^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $1.83 vs $0.97 beat^[FMP], stock +0.6% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $336.0M^{[FMP cashflow]}. Q1 op margin 5.1%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $130 (+4.0% upside vs current $125) - **High / Low:** $150 / $117 - **Buy / Hold / Sell:** 8 / 1 / 0 - **Analyst count:** 2 (last quarter), 19 all-time ## Additional Transcript Insights ### 1. fy26_eps_guidance **Claim:** Bunge is increasing its full year 2026 adjusted EPS guidance from $7.50-$8.00 to $9.00-$9.50. **Evidence (transcript):** "Based on what we can see today, including the strength of Q1 and the forward curves as we look at the balance of the year, we are increasing our full year adjusted EPS guidance range to $9 to $9.50, and that's up from the $7.50 to $8 we provided on our fourth quarter call." **Numbers:** $9, $9.50, $7.50, $8 ### 2. soybean_softseed_processing_refining **Claim:** Bunge expects Soybean and Softseed Processing and Refining segment results to be higher for full year 2026. **Evidence (transcript):** "For the full year compared to our previous outlook, Soybean and Softseed Processing and Refining segment results are forecasted to be higher." **Numbers:** — ### 3. tropical_oils_specialty_ingredients_grain_merchandising_milling **Claim:** Bunge expects Tropical Oils and Specialty Ingredients and Grain Merchandising and Milling segment results to be lower for full year 2026. **Evidence (transcript):** "Tropical Oils and Specialty Ingredients and Grain Merchandising and Milling segment results are expected to be lower and corporate and other results are expected to be in line." **Numbers:** — ### 4. net_interest_expense_guidance **Claim:** Bunge now expects net interest expense in the range of $620 million to $660 million for 2026, which is up from its previous range of $575 million to $625 million. **Evidence (transcript):** "Net interest expense in the range of $620 million to $660 million, which is up from our previous range of $575 million to $625 million, primarily due to higher short-term debt levels supporting an expected increase in working capital." **Numbers:** $620 million, $660 million, $575 million, $625 million ### 5. capex_guidance **Claim:** Bunge expects capital expenditures in the range of $1.5 billion to $1.7 billion for 2026. **Evidence (transcript):** "Capital expenditures in the range of $1.5 billion to $1.7 billion and depreciation and amortization of approximately $975 million." **Numbers:** $1.5 billion, $1.7 billion, $975 million ### 6. viterra_synergies **Claim:** Bunge notes that Viterra cost synergies are running ahead of plan, and they've identified significant network and commercial opportunities. **Evidence (transcript):** "Viterra cost synergies are running ahead of plan, and we've identified significant network and commercial opportunities." **Numbers:** — --- *Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*